Bringing the fundamentals into focus…
Back to Eli Lilly and Company
How Eli Lilly and Company stacks up
LLY · against 1 other Healthcare companies of similar size
Valuation
50/ 100
Near the bottom of its peers.
Ranked #2 of 2 · scores higher than 0% of peers
Bars: peers in each 10-point band of the valuation score1 peers with a valuation score of 50–59, including LLY · Click a bar to see the companies
Why valuation scores 50?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 3.1% vs peer median 3.9%
- Earnings yield is close to the peer norm. Earnings yield: 2.4% vs peer median 1.4%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.3% vs peer median 0.0%
Metric by metric
Position: dot = LLY, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LLY | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 2 reported | 2.5% | 2.9% | 0% | 30% | |
| EBITDA yieldHigher is better · 2 reported | 3.8% | 4.6% | 0% | 50% | |
| Free cash flow yieldHigher is better · 2 reported | 1.3% | 2.4% | 0% | 20% | |
| Book yieldHigher is better · 2 reported | 3.2% | 8.4% | 0% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around LLY| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 622.8B USD | 60 | 59 | |
| 2 | 1.06T USD | 50 | 63 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score